How We Help

Providing contextualized market insights, helping to identify new opportunities, minimize risk, and gain a competitive advantage.

Evaluate’s suite of forecasting solutions enables you to make confident investment, partnering, and commercial decisions. Gold-standard consensus forecasts provide an unmatched view into your markets, while custom forecast models, and proprietary analogs enable you to develop informed forecasts for your key assets. The result? A comprehensive view of the market – and your place in it.

Forecasting & Market Sizing

Find out more

Every deal is different and requires a clear view of potential partners, comparable deals, and market potential. To support you, we go beyond asset assessment. Our solutions provide a systematic approach to enable you to compare candidates based on commercial, clinical, and scientific criteria such as market novelty, potential revenue, competitive intensity, and partner suitability.

Business Development & Licensing

Find out more

In an ever-evolving market landscape, you must understand the intricacies of clinical and commercial differentiation. Our comprehensive suite of solutions and insights give you the competitive edge you need to navigate the market’s complexities, optimize your pipeline, develop comprehensive scenario planning, and prioritize the right indications.

Portfolio Strategy

Find out more

For biotech and pharma companies alike, a comprehensive view of the competitive landscape is vital. Evaluate’s blend of data-driven solutions and expert analysis provide real-time tracking, analysis, and strategic intelligence to support decision-making processes across drug development, manufacturing, and market competition. So nothing need take you by surprise.

Competitive Intelligence

Find out more

No two pharma companies are alike and no two challenges are the same. When you need tailored support to answer specific challenges, Evaluate’s advisory solutions provide the perfect blend of insight and expertise.

Leveraging a foundation of extensive Evaluate data, augmented with secondary research, modelling and analysis, our pharmaceutical consulting solutions are data-driven and insight-focused. We also conduct targeted primary research with key opinion leaders, healthcare professionals and payers to validate our assumptions and test our hypotheses.

As part of Norstella, our team has access to an unparalleled range of insights, expertise and deep industry knowledge.

Learn more about how our consultants can help you

Get in touch to speak to request tailored support

Consulting & Analytics

References

1 - https://www.congress.gov/congressional-record/volume-172/issue-24/house-section/article/H1960-1

2 - https://jamanetwork.com/journals/jama/article-abstract/2842439

3 - https://download.open.fda.gov/crl/CRL_NDA219398_20260128.pdf

4 - https://www.accessdata.fda.gov/scripts/opdlisting/oopd/

5 - https://everylifefoundation.org/wp-content/uploads/2024/12/UltraRareSummary.pdf

6 - https://insilico.com/pipeline_target_targetx

7 - https://pmc.ncbi.nlm.nih.gov/articles/PMC11208459/#s4

8 - https://www.brookings.edu/articles/estimated-savings-from-year-two-of-the-ira-prescription-drug-negotiation-program/

9 - https://pmc.ncbi.nlm.nih.gov/articles/PMC12577718/

10 - https://www.nejm.org/doi/full/10.1056/NEJMsb2512695

11 - https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-plausible-mechanism-framework-develop-individualized-therapies-target-specific